Novel developments in angiogenesis cancer therapy

por Hirte, H.W.
Publicado 2009

Human ovarian carcinoma: evidence for patient-related differences in susceptibility to cytotoxic effectors that attack different cellular subpopulations within a tumour.

por Clark, D. A., Hirte, H. W., Buick, R. N.
Publicado 1988

Optimal chemotherapy treatment for women with recurrent ovarian cancer

por Fung-Kee-Fung, M., Oliver, T., Elit, L., Oza, A., Hirte, H.W., Bryson, P.
Publicado 2007

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

por Razak, A R A, Hotte, S J, Siu, L L, Chen, E X, Hirte, H W, Powers, J, Walsh, W, Stayner, L-A, Laughlin, A, Novotny-Diermayr, V, Zhu, J, Eisenhauer, E A
Publicado 2011

A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)

por Sahebjam, S, Bedard, P L, Castonguay, V, Chen, Z, Reedijk, M, Liu, G, Cohen, B, Zhang, W-J, Clarke, B, Zhang, T, Kamel-Reid, S, Chen, H, Ivy, S P, Razak, A R A, Oza, A M, Chen, E X, Hirte, H W, McGarrity, A, Wang, L, Siu, L L, Hotte, S J
Publicado 2013